Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tripelennamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.97 |
| ▸ | DRD1 | P21728 | 4/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | HTR2A | P28223 | 3/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tripelennamine SCHEMBL98916 | 1.00 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL17970 | 0.98 | CHRM2 (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL29600775 | 0.98 | CHRM2 (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL1652325 | 0.97 | CHRM2 (0.97) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL15270438 | 0.93 | CHRM2 (0.89) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Chloropyramine SCHEMBL13723581 | 0.90 | CYP2D6 (0.95) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL5432608 | 0.89 | CHRM2 (0.82) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Chloropyramine SCHEMBL34463428 | 0.88 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Hydrochloric Acid SCHEMBL29763485 | 0.88 | KDM4E (0.79) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Chloropyramine SCHEMBL538104 | 0.88 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | disclosed |
| CN-119868249-A | Transdermal delivery formulation | 阿尔伯特爱因斯坦医学院 | 2025-04-25 | — | — | CN | disclosed |
| CN-119555825-A | Method for rapidly determining 17 novel veterinary drug compounds in animal-derived food by combining solid phase extraction with HPLC-MS/MS method | 成都海关技术中心 | 2025-03-04 | — | — | CN | disclosed |
| EP-3806859-B1 | METHOD OF TREATMENT WITH HISTAMINE-3 RECEPTOR INVERSE AGONIST | SUVEN LIFE SCIENCES LTD (IN) | 2025-01-22 | — | — | EP | disclosed |
| CN-119125346-A | Method for determining 19 novel veterinary drug residues in animal-derived food based on modified QuEChERS-HPLC-MS/MS method | 成都海关技术中心 | 2024-12-13 | — | — | CN | disclosed |
| CN-119033816-A | Mesenchymal stem cells, therapeutic agent for immune disease, and anti-inflammatory agent | 日本乐敦制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| CN-112513297-B | Identification of epigenetic changes in DNA isolated from exosomes | 得克萨斯州大学系统董事会 | 2024-10-22 | — | — | CN | disclosed |
| CN-113164770-B | Mesenchymal stem cells, therapeutic agent for immune disease, and anti-inflammatory agent | 日本乐敦制药株式会社 | 2024-07-19 | — | — | CN | disclosed |
| EP-3334820-B1 | INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USING | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-113423436-B | Microbiota metabolites that shape host physiology | 耶鲁大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-116848247-A | anti-TNFR 2 antibodies and uses thereof | 宝船生物医药科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3576724-B1 | CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF MAST CELL-ASSOCIATED OR BASOPHIL-MEDIATED INFLAMMATORY DISORDERS | GBS GLOBAL BIOPHARMA INC (CA) | 2023-09-27 | — | — | EP | disclosed |
| CN-112566933-B | anti-CD 40 antibodies and uses thereof | 祐和医药科技(北京)有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116333123-A | anti-TNFR 2 antibodies and uses thereof | 宝船生物医药科技(上海)有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4185997-A1 | DOSE COUNTER ASSEMBLIES FOR MEDICAMENT DISPENSERS | Lupin Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11426392-B1 | Antiviral and virucidal lung nebulizer compositions and related treatment methods | FERRER MEDICAL INNOVATIONS, LLC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11395819-B1 | Antiviral and virucidal lung nebulizer compositions and related treatment methods | Ferrer Medical Innovations, LLC (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2022131880-A2 | PHARMACEUTICALLY STABLE SOFT CAPSULE COMPRISING TWO OR MORE DIFFERENT COMPOSITIONS | 코스맥스파마 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| WO-2022020506-A1 | DOSE COUNTER ASSEMBLIES FOR MEDICAMENT DISPENSERS | Lupin Inc. (US) | 2022-01-27 | — | — | WO | disclosed |